Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive September 1, 2012 Bill Trombetta	Pharm Exec's 11th Annual Industry Audit: Busting the Tape With pharmaceuticals are eyed as a commodity purchase, those traditional high margins are getting harder to find. Shareholder value and profits now depends on finding pockets of "good" growth, in segments with long-term potential in serving an unmet medical need, with fewer players.
Pharmaceutical Executive September 1, 2011	Pharm Exec's 10th Annual Industry Audit A survey of the landscape of pharma financials over the past year, and a look at which companies rode the wave to the top of the industry in delivering value to shareholders.
Pharmaceutical Executive September 1, 2010	Pharm Exec's Ninth Annual Industry Audit Professor Bill Trombetta takes a snapshot of the "Glamour 24" companies shaping the pharma industry this year and beyond.
Pharmaceutical Executive September 1, 2006 Bill Trombetta	Industry Audit This fifth annual report dives deep into the numbers and comes up with the pharmaceutical industry's true top performers.
Pharmaceutical Executive September 1, 2005 Bill Trombetta	2005 Industry Audit Who's really on top in the pharmaceutical industry?
Pharmaceutical Executive June 1, 2009	Stealth Pharmas These noteworthy pharmas and biotechs generally fly under the radar (ergo "stealth") of the mainstream media.
Pharmaceutical Executive April 1, 2007 Bill Trombetta	Stealth Pharmas Big Pharma is different from the thousands of biotechs, specialty pharmas, generics makers, and other companies that make up Stealth Pharma. Yes, they have more money. But in what other ways are they different? And can we learn anything from the way Stealth Pharma competes?
Pharmaceutical Executive September 1, 2014 William Looney	13 Years Right Pharm Exec's latest Industry Audit sticks to the series' longtime standard of emphasizing transparent indicators of shareholder value.
The Motley Fool October 18, 2010 Gerard Torres	Every Investor Should Know This Stock Tool Use DuPont analysis to breakdown the profitability of stocks.
Pharmaceutical Executive June 9, 2014 Cliff Kalb	The Urge to Merge Deal making lessons for pharmaceutical companies from history's storyboard.
Pharmaceutical Executive January 1, 2014 Stan Bernard	The 7 Habits of Highly Effective Competitions Lessons to win in a shifting market dynamic
Pharmaceutical Executive November 1, 2012	Pharm Exec's 2013 Pipeline Report In this year's report, Ben Comer reveals that drug approvals are up, as new discoveries in biology peel away symptomology to expose underlying causes.
The Motley Fool May 23, 2011 Andrew Tonner	Does Amgen Deserve a Spot in Your Portfolio? Depending on your assessment of future growth, Amgen could certainly make a nice addition to your portfolio.
Chemistry World January 6, 2015 Sarah Houlton	Riding new waves Global annual spending on medicines is set to top $1 trillion for the first time in 2014, having ended 2013 just shy of that figure at $989 billion.
Pharmaceutical Executive September 1, 2010	Is There a Balm for Gilead? A new leader, a big acquisition, and a bold investment in HIV may all be in the works at Gilead. But what will it take to restore the glory days?
The Motley Fool February 10, 2010 Brian Orelli	Icahn's Smiling -- Should We Be? Biogen Idec's fourth quarter results must have made Carl Icahn smile. But the guidance for next year gives pause.
The Motley Fool December 30, 2005	Foolish Fundamentals: Return on Invested Capital Investors, learn to measure how much value a company creates.
Pharmaceutical Executive November 1, 2014 William Looney	Dane in America Jesper Hoiland, Novo Nordisk's President for North America, assesses the challenges and opportunities during his first year at the helm of the diabetes franchise leader's biggest affiliate market.
Pharmaceutical Executive March 1, 2006 Cacciotti & Shew	Pharma's Next Top Model: Slimmer Business Models After almost two decades of blockbuster-driven prosperity, the model for success in pharmaceuticals has broken down. The path forward, once clear, is no longer obvious.
Pharmaceutical Executive May 1, 2012	Pharm Exec 50: Growth from the Bottom Up More consolidation didn't boost pharmaceutical sales at the top, but a handful of nimble newcomers posted impressive growth on the other end of the curve.
Chemistry World September 10, 2015 Katrina Megget	Merger fever sweeps pharma Cheap financing, among other factors, is allowing companies to stock their drug pipelines through acquisitions
Pharmaceutical Executive January 21, 2014 Tim Powell	Innovation: The Moneyball Test Successful innovation now has to align with key metrics of value; can an old baseball metaphor help guide the way?
Chemistry World December 17, 2015 Sarah Houlton	Pills, prices and politics Pharmaceutical pricing has been a hot topic in 2015, with the drugs bill continuing to rise as costly new treatments reach the market.
The Motley Fool November 30, 2009 Brian Orelli	Making Money More Efficiently Drug companies shape up, and it shows in their margins.
Pharmaceutical Executive April 1, 2011	Winning Beyond the Molecule It can take both a clinical and non-clinical approach to win the differentiation competition.
IndustryWeek July 20, 2011	IW 50 Best Manufacturers: Methodology How IW ranked the Top 50
Pharmaceutical Executive July 1, 2009 Stan Bernard	Forget Brand vs. Brand--This is War Increasingly, pharma companies are expanding from brand vs. brand to battle at the franchise, portfolio, and corporate levels.
IndustryWeek June 23, 2010	IW 50 Best U.S. Manufacturers -- 2010 Methodology The formula to find the top 50 U.S. manufacturers factors in revenue growth, profit margins, return on equity, return on assets and asset turnover, and inventory turns.
The Motley Fool July 28, 2010 Sean Sun	Risk Report Card: Procter & Gamble The power of its brands, from its Gillette razors to its Pampers diapers, gives it premium pricing power and an edge over its competitors.
The Motley Fool August 27, 2011 Dan Radovsky	A Surprisingly Good Return on a Scary Day Take a look at two bellwethers. Coca-Cola and PepsiCo are two examples of what are thought to be solidly run, profitable companies that have paid back their investors with decent growth in value and in dividends.
The Motley Fool August 6, 2010 Bryan Hinmon	Moat Report Card: Medtronic This medical supplier's definitely got a heartbeat.
Pharmaceutical Executive May 1, 2012 William Looney	Seeding Beyond the Base The pharmaceutical industry's reputation as a growth industry no one wants to pay for is more secure than ever.
The Motley Fool November 7, 2011 Dan Caplinger	Has Pfizer Become the Perfect Stock? The pharma giant still faces the challenge of patent expirations that could outpace its pipeline development.
Chemistry World February 25, 2014 Sarah Houlton	Megamerger brings Actavis into R&D race Generic drug giant Actavis is to buy speciality pharmaceutical firm Forest Labs in a deal worth about $25 billion, bringing Actavis into the drug discovery business.
The Motley Fool March 11, 2005 Karl Thiel	Better Times at Biogen IDEC Is now the time to buy this pharmaceutical?
Pharmaceutical Executive September 1, 2012 William Looney	The Margin Call Autumn is a good time to present our annual post on how well the industry is doing in harvesting value for shareholders. Our diverse list of 24 companies, drawn from Big Pharma to the established biotechs, presents a similarly mixed picture on returns.
The Motley Fool July 9, 2009 Selena Maranjian	This Metric Can Lead You to Winners Of all the measures you can use to search for quality companies, the metric known as return on invested capital can be one of the trickiest. But it's one way to find great businesses.
The Motley Fool July 23, 2010 Bryan White	3 Buys Suffering From the Health-Care Hangover Three ideas in value territory for a much-needed sector.
The Motley Fool June 30, 2010 Brian Orelli	Which Midsized Biotech Is the Best Buy? Biogen Idec, Amgen, or Gilead? Which of these biotechs has the most potential for growth?
Pharmaceutical Executive June 9, 2014 William Looney	Pharma 50 Trends: Past, Present, and Future Finding the correct coordinates for big Pharma's endless cycle of re-positioning is just as important as a winning scientific hand.
The Motley Fool March 8, 2005 Charly Travers	After the Crash, Is Biogen IDEC a Buy? Biogen stock plunge may be an overreaction to pulling multiple sclerosis drug Tysabri off the market.
The Motley Fool January 18, 2011 Jim Royal	How Do These Biotechs Really Make Their Money? Break it down using the Dupont formula.
The Motley Fool July 30, 2010 Bryan Hinmon	Moat Report Card: Home Depot A look at the home improvement retailer's competitive positioning.
The Motley Fool October 30, 2010 Anand Chokkavelu	7 Pharma Stocks Near 52-Week Highs Here are the top seven companies in the pharmaceutical space (by market cap) that are within spitting distance of their 52-week highs: J&J... Novartis... Merck... GlaxoSmithKline... Abbott... AstraZeneca... Novo Nordisk...
The Motley Fool March 29, 2010 Brian Orelli	5 Drugmakers Producing Cash for You Take greenbacks over earnings any day.
CFO June 1, 2007 Scott Leibs	Measuring Up Many companies still struggle to use metrics effectively. It may be that fresh thinking is what really counts.
The Motley Fool October 25, 2011 Igor Meyerson	How Do the 7 Largest Auto Companies Stack Up Against Each Other? A look into which auto manufacturer has the best financials.
The Motley Fool August 24, 2011 Andrew Tonner	Does Abbott Laboratories Look Like a Winning Investment? A quick check of their numbers shows us that Abbott Labs looks reasonably attractive.
The Motley Fool February 28, 2006 Stephen D. Simpson	Still Waiting for Teva to Stumble This leading Israeli generics firm hasn't seen a stock pullback of any consequence since mid- to late 2004. And while fourth-quarter results weren't fabulous, they were good enough given the circumstances
The Motley Fool July 18, 2008 Brian Lawler	Still Liking Gilead, Warts and All Don't look past a few issues, even though Gilead still has a bright future.